Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Ono Files BTK inhibitor Tirabrutinib in Japan for Primary CNS Lymphoma
August 29, 2019
- Kyowa Kirin Finally Bags US OK for Parkinson’s Disease Istradefylline
August 29, 2019
- Mitsubishi Tanabe Launches US PIII Study of Continuous SC Liquid Levodopa/Carbidopa for Parkinson’s Disease
August 29, 2019
- Towa, Kyoto iPS Upstart Eye Repositioning of Generic Drug for Alzheimer’s
August 27, 2019
- Amicus Raises Its Hands for Sly Syndrome Drug Development in Japan
August 27, 2019
- Kyowa Kirin Starts Japan PIII of Lumicef for Palmoplantar Pustulosis
August 27, 2019
- Nasonex Authorized Generic Now Available
August 26, 2019
- Sawai Aims to See “Branded Generics” Account for One-Third of Its Product Lineup in US in 2024
August 26, 2019
- Astellas/Pfizer’s Xtandi Given FDA’s Priority Review for Hormone-Sensitive Prostate Cancer
August 23, 2019
- Pfizer Launches Herceptin Biosimilar in Japan
August 23, 2019
- Price Revision Rates in October Re-Pricing Vary in Crowded DPP-4 Class: Survey
August 22, 2019
- Celltrion/Nippon Kayaku Herceptin Biosimilars Get OK for New Breast Cancer Dosing Schedule
August 22, 2019
- GSK’s Daprodustat Reaches 1st NDA Filing, in Japan
August 22, 2019
- NEDO to Subsidize Development of FunPep’s Antibody-Inducing Peptide for Psoriasis Treatment
August 22, 2019
- Tomita Pharmaceutical Invests in Wearable Medical Device Startup
August 22, 2019
- Frontloaded Price Cuts before Regular April Revision Hurts, Say Drug Makers
August 21, 2019
- Teva Takeda to License 10 APIs/20 Products from Sawai as It Plans to Shutter In-House Plants
August 21, 2019
- Big 3 Generic Players Braced for Average 9.2% Price Cut in October Re-Pricing
August 20, 2019
- Tax Hike Re-Pricing Slams Small Pharma and Gx Players, Impact Milder for Big Firms: Survey
August 20, 2019
- Sumitomo Dainippon Flip-Plops on Sales Force Cutback as It Ramps Up Diabetes Push
August 19, 2019
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…